Related Experiment Video

Updated: Aug 10, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug

N Osheroff1, A H Corbett, S H Elsea

  • 1Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146.

Cancer Chemotherapy and Pharmacology
|January 1, 1994
PubMed

Insights

Four cancer drugs, including etoposide and amsacrine, target the same site on topoisomerase II (an enzyme crucial for DNA replication). This finding helps explain how these antineoplastic agents work.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Topoisomerase II (an enzyme essential for DNA replication and repair) is a key target for many cancer chemotherapy drugs.
  • These drugs function by stabilizing an intermediate state where the enzyme cleaves DNA, leading to cell death.
  • Despite a common mechanism, differences in how various drug classes affect enzyme activity have been observed.

Purpose of the Study:

  • To investigate whether structurally diverse anticancer drugs targeting topoisomerase II interact at a common site or distinct sites on the enzyme.
  • To elucidate the precise molecular interactions between topoisomerase II and different classes of antineoplastic agents.

Main Methods:

  • Utilized competition experiments to assess drug interactions with topoisomerase II.
  • Analyzed mechanistic differences in drug effects on DNA cleavage/religation, DNA strand passage, and ATP hydrolysis.

Main Results:

  • Evidence strongly suggests that etoposide, amsacrine, genistein, and CP-115,953 interact within an overlapping domain on topoisomerase II.
  • These structurally disparate drugs appear to share a common binding site or region on the target enzyme.

Conclusions:

  • The findings indicate a shared interaction domain on topoisomerase II for multiple anticancer drugs, despite their structural differences.
  • This shared site of action has significant implications for understanding drug mechanisms and developing new cancer therapies targeting topoisomerase II.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Concept Videos

Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...